American Journal of Infectious Diseases and Microbiology
ISSN (Print): 2328-4056 ISSN (Online): 2328-4064 Website: Editor-in-chief: Maysaa El Sayed Zaki
Open Access
Journal Browser
American Journal of Infectious Diseases and Microbiology. 2021, 9(3), 90-97
DOI: 10.12691/ajidm-9-3-3
Open AccessReview Article

SARS-CoV-2 Genetic Variations, Immunity, and Efficacy of Vaccines: The Current Perspectives and Future Implications

Venkataramana Kandi1,

1Member, Asian Council for Science Editors (ACSE), Department of Microbiology, Prathima Institute of Medical Sciences, Karimnagar, Telangana, India

Pub. Date: August 04, 2021

Cite this paper:
Venkataramana Kandi. SARS-CoV-2 Genetic Variations, Immunity, and Efficacy of Vaccines: The Current Perspectives and Future Implications. American Journal of Infectious Diseases and Microbiology. 2021; 9(3):90-97. doi: 10.12691/ajidm-9-3-3


From the time since its discovery, the novel SARS-CoV-2 had spread throughout the world and has been a challenge for the healthcare system to control its spread and manage the infected patients. Although the mortality rates varied around the globe, what was common was the impact of COVID-19 on the societal, cultural, political, and economic aspects. With no specific anti-viral drug available, the initial days of the pandemic were even more stressful and resulted in increased morbidity and mortality. Gradually, by the observations, and studies of clinicians and scientists, we could improve our knowledge regarding the nature of the virus, its potential origins, pathogenic mechanisms, methods of diagnosis, treatment, and effective strategies for the management of COVID-19 patients. Interestingly, the virus had been found mutating, and therefore, even after more than a year into the pandemic, we still are putting up a fight against the novel virus. Availability of the vaccine, despite hesitancy, has been the high point in the current pandemic. Molecular studies have revealed thousands of SARS-CoV-2 variants spread throughout the world. Several countries have been experiencing waves of infection forcing restricted people movements and lockdowns. The variability in the infection rates and intensities influenced by age, gender, and other factors remain to be completely understood. Efficacy of the vaccines, their safety, immune responses against SARS-CoV-2 infections has been at the forefront of the research studies. In this review, we discuss the molecular and immunological aspects of SARS-CoV-2 infection with a note on the current perspectives and future implications of the virus and vaccine research.

SARS-CoV-2 COVID-19 molecular studies immunological aspects vaccine research

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Kandi V. Coronavirus Disease (COVID-19)/SARS-CoV-2: Hopefully, the Human-Virus Battle Ends Soon on a Positive Note. Perspectives in Medical Research 2020; 8(1): 1-3.
[2]  Mohapatra, R.K., Pintilie, L., Kandi, V., Sarangi, A.K., Das, D., Sahu, R. and Perekhoda, L. (2020), The recent challenges of highly contagious COVID-19; causing respiratory infections: symptoms, diagnosis, transmission, possible vaccines, animal models and immunotherapy. Chem Biol Drug Des. Accepted Author Manuscript.
[3]  Pal M, Berhanu G, Desalegn C, Kandi V, (March 26, 2020) Severe Acute Respiratory Syndrome Coronavirus2 (SARS-CoV-2): An Update. Cureus 12(3): e7423.
[4]  Pal, M, Kerorsa,G.B. and Kandi,V. A Knowledge Update on SARS-Coronavirus-2 (SARS-CoV-2)/COVID-19 and Its Global Public Health Implications. American Journal of Clinical Medicine Research 8. 1 (2020): 23-27.
[5]  Kandi V, Thungaturthi S, Vadakedath S, Gundu R, Mohapatra RK. Mortality Rates of Coronavirus Disease 2019 (COVID-19) Caused by the Novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Cureus. 2021 Mar 24; 13(3): e14081.
[6]  Jenner E. An Inquiry into the Causes and Effects of VariolaeVaccinae: A Disease Discovered in Some Western Counties of England. London: Sampson Low (1798). P. 75.
[7]  Pasteur L. Sur les maladies virulentes, et en particuliersur la maladieappeleevulgairement cholera des poules. C R AcadSci (1880) 90:249-248.
[8]  Pasteur L. Methode pour prevenir la rage apresmorsure. C R AcadSci (1885) 101:765-74.
[9]  Pasteur L, Chamberland C, Roux E. Compterendusommaire des experiences faites a Pouilly-Le-Fort, pres de Melun, sur la vaccination charnonneuse. C R AcadSci (1881) 92: 1378-83.
[10]  Jerne NK, Nordin AA. Antibody formation in agar by single anibody-producing cells. Science (1963) 140:405.
[11]  Udwadia ZF, Tripathi AR, Nanda VJ, Joshi SR. Prognostic Factors for Adverse Outcomes in COVID-19 Infection. J Assoc Physicians India. 2020 Jul; 68(7): 62-66.
[12]  Wendel Garcia PD, Fumeaux T, Guerci P, HeubergerDM, Montomoli J, Roche-Campo F, Schuepbach RA, Hilty MP; RISC-19-ICU Investigators. Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort. EClinicalMedicine. 2020 Aug; 25: 100449.
[13]  Vadakedath S, Kandi V, Mohapatra RK, PinnelliVBK, Yegurla RR, Shahapur PR, Godishala V, Natesan S, Vora KS, Sharun K, Tiwari R, Bilal M, Dhama K. Immunological aspects and gender bias during respiratory viral infections including novel Coronavirus disease-19 (COVID-19): A scoping review. J Med Virol. 2021 Sep; 93(9): 5295-5309.
[14]  Kim HK, Yoon SW, Kim DJ, et al. Detection of Severe Acute Respiratory Syndrome-Like, Middle East Respiratory Syndrome-Like Bat Coronaviruses and Group H Rotavirus in Faeces of Korean Bats. TransboundEmerg Dis. 2016; 63(4): 365-372.
[15]  Allocati N, Petrucci AG, Di Giovanni P, Masulli M, Di Ilio C, De Laurenzi V. Bat-man disease transmission: zoonotic pathogens from wildlife reservoirs to human populations. Cell Death Discov. 2016; 2: 16048. Published 2016 Jun 27.
[16]  Ramos-Nino ME, Fitzpatrick DM, Eckstrom KM, Tighe S, Dragon JA, Cheetham S. The Kidney-Associated Microbiome of Wild-Caught Artibeus spp. in Grenada, West Indies. Animals (Basel). 2021; 11(6): 1571. Published 2021 May 27.
[17]  Lauring AS, HodcroftEB. Genetic Variants of SARS-CoV-2-What Do They Mean? JAMA. 2021 Feb 9; 325(6): 529-531.
[18]  Hou YJ, Chiba S, Halfmann P, Ehre C, Kuroda M, DinnonKH 3rd, Leist SR, Schäfer A, Nakajima N, Takahashi K, Lee RE, Mascenik TM, Graham R, Edwards CE, Tse LV, Okuda K, MarkmannAJ, Bartelt L, de Silva A, Margolis DM, Boucher RC, Randell SH, Suzuki T, Gralinski LE, Kawaoka Y, Baric RS. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science. 2020 Dec 18; 370(6523): 1464-1468.
[19]  Arora P, Pöhlmann S, Hoffmann M. Mutation D614G increases SARS-CoV-2 transmission. Signal Transduct Target Ther. 2021; 6(1): 101. Published 2021 Mar 1.
[20]  Bayarri-Olmos R, Rosbjerg A, JohnsenLB, Helgstrand C, Bak-Thomsen T, Garred P, Skjoedt MO. The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization. J Biol Chem. 2021 Jan-Jun; 296: 100536.
[21]  Zuckerman NS, Fleishon S, Bucris E, Bar-Ilan D, Linial M, Bar-Or I, Indenbaum V, Weil M, Lustig Y, Mendelson E, Mandelboim M, Mor O, Zuckerman N, On Behalf Of The Israel National Consortium For Sars-CoV-Sequencing. A Unique SARS-CoV-2 Spike Protein P681H Variant Detected in Israel. Vaccines (Basel). 2021 Jun 8; 9(6): 616.
[22]  Bugembe DL, PhanMVT, Ssewanyana I, Semanda P, Nansumba H, Dhaala B, Nabadda S, O'Toole ÁN, Rambaut A, Kaleebu P, Cotten M. Emergence and spread of a SARS-CoV-2 lineage A variant (A.23.1) with altered spike protein in Uganda. Nat Microbiol. 2021 Jun 23.
[23]  SARS-CoV-2 Variant Classifications and Definitions.
[24]  Global Lineage Reports.
[25]  Helping track the transmission and spread of SARS-CoV-2.
[26]  Áine O’Toole, Emily Scher, Anthony Underwood, Ben Jackson, Verity Hill, John T McCrone, Rachel Colquhoun, Chris Ruis, Khalil Abu-Dahab, Ben Taylor, Corin Yeats, Louis Du Plessis, Daniel Maloney, Nathan Medd, Stephen W Attwood, David M Aanensen, Edward C Holmes, Oliver G Pybus, Andrew Rambaut, Assignment of Epidemiological Lineages in an Emerging Pandemic Using the Pangolin Tool, Virus Evolution, 2021;, veab064.
[27]  O'Toole Á, Hill V, PybusOG, et al. Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2. Wellcome Open Res. 2021; 6: 121. Published 2021 May 19.
[28]  Rambaut A, Holmes EC, O'Toole Á, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol. 2020; 5(11): 1403-1407.
[29]  Jagannathan, P., Wang, T.T. Immunity after SARS-CoV-2 infections. Nat Immunol 22, 539-540 (2021).
[30]  RoddaLB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD, TakeharaKK, Eggenberger J, HemannEA, Waterman HR, Fahning ML, Chen Y, Hale M, Rathe J, Stokes C, Wrenn S, Fiala B, Carter L, HamermanJA, King NP, Gale M Jr, Campbell DJ, Rawlings DJ, Pepper M. Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. Cell. 2021 Jan 7; 184(1): 169-183. e17.
[31]  Zhou W, Xu X, Chang Z, Wang H, Zhong X, Tong X, Liu T, Li Y. The dynamic changes of serum IgM and IgG against SARS-CoV-2 in patients with COVID-19. J Med Virol. 2021 Feb; 93(2): 924-933.
[32]  Qu J, Wu C, Li X, Zhang G, Jiang Z, Li X, Zhu Q, Liu L. Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Nov 19; 71(16): 2255-2258.
[33]  Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, Nakao C, Rayaprolu V, Rawlings SA, Peters B, Krammer F, Simon V, SaphireEO, Smith DM, Weiskopf D, Sette A, Crotty S. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021 Feb 5; 371(6529): eabf4063.
[34]  Cromer D, Juno JA, Khoury D, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol. 2021; 21(6): 395-404.
[35]  Chakraborty S, Mallajosyula V, Tato CM, Tan GS, Wang TT. SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand? Adv Drug Deliv Rev. 2021 May; 172: 314-338.
[36]  Stern PL. Key steps in vaccine development. Ann Allergy Asthma Immunol. 2020 Jul; 125(1): 17-27.
[37]  Coronavirus disease (COVID-19): Vaccines.{adgroupsurvey}&gclid=Cj0KCQjw6NmHBhD2ARIsAI3hrM36W0oTULjb 0xbxpiHigj6TEwkVPjLUbJD3ADW6nb8fsOdaQbpKVNYaAuB-EALw_wcB.
[38]  COVID-19 vaccine tracker and landscape.
[39]  Hodgson SH, Mansatta K, Mallett G, Harris V, EmaryKRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021 Feb;21(2):e26-e35.
[40]  Ura T, Yamashita A, Mizuki N, Okuda K, Shimada M. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Vaccine. 2021 Jan 8; 39(2): 197-201.
[41]  Koike H, Chiba A, Katsuno M. Emerging Infection, Vaccination, and Guillain-Barré Syndrome: A Review. NeurolTher. 2021 Jun 12: 1-15.
[42]  Papa A, Scaldaferri F, Vetrone LM, Neri M, Gasbarrini A, LopetusoLR. How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists. Vaccines (Basel). 2021; 9(3): 248. Published 2021 Mar 12.
[43]  Zheng C, Kar I, Chen CK, Sau C, Woodson S, Serra A, Abboud H. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination. CNS Drugs. 2020 Sep; 34(9): 879-896.
[44]  Kanimozhi G, Pradhapsingh B, Singh Pawar C, Khan HA, AlrokayanSH, Prasad NR. SARS-CoV-2: Pathogenesis, Molecular Targets and Experimental Models. Front Pharmacol. 2021 Apr 22; 12: 638334.
[45]  Liu X, Zaid A, Freitas JR, McMillan NA, Mahalingam S, Taylor A. Infectious Clones Produce SARS-CoV-2 That Causes Severe Pulmonary Disease in Infected K18-Human ACE2 Mice. mBio. 2021 Apr 20; 12(2): e00819-21.
[46]  Rathnasinghe R, Strohmeier S, Amanat F, Gillespie VL, Krammer F, García-Sastre A, Coughlan L, Schotsaert M, Uccellini MB. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerg Microbes Infect. 2020 Dec; 9(1): 2433-2445.
[47]  Case JB, Winkler ES, ErricoJM, Diamond MS. On the road to ending the COVID-19 pandemic: Are we there yet?. Virology. 2021; 557: 70-85.
[48]  Bakhshandeh B, SorboniSG, Javanmard AR, Mottaghi SS, Mehrabi MR, Sorouri F, Abbasi A, Jahanafrooz Z. Variants in ACE2; potential influences on virus infection and COVID-19 severity. Infect Genet Evol. 2021 Jun; 90: 104773.
[49]  Shapiro RS. COVID-19 vaccines and nanomedicine. Int J Dermatol. 2021 Jun 5:10.1111/ijd.15673.
[50]  Kiesslich S, Kim GN, Shen CF, Kang CY, Kamen AA. Bioreactor production of rVSV-based vectors in Vero cell suspension cultures. BiotechnolBioeng. 2021 Jul; 118(7): 2649-2659.